Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial

H. Ludwig, A. Cortelezzi, W. Scheithauer, B. G K van Camp, R. Kuzmits, G. Fillet, M. Peetermans, E. Polli, R. Flener

Research output: Contribution to journalArticle

Abstract

Forty-two previously untreated patients with multiple myeloma were entered in a prospective, randomised trial comparing recombinant interferon alfa-2C monotherapy with VMCP (vincristin, melphalan, cyclophosphamide and prednisolone). Both treatment arms were comparable for the stratification variables such as paraprotein type, stage of disease, and renal function. Rec. interferon effected 14% responses and 29% minor responses, while 57 and 32% of VMCP-treated patients achieved a pathologically documented remission (P <0.001). The time on initial treatment was significantly shorter in the IFN group (3.2 months) than in the VMCP group (7.6 months). In four patients in the IFN arm, primary treatment had to be changed according to progressive or severe stationary disease. Since all four patients responded to second line therapy (VMCP) no significant difference has been observed between the two groups in survival (median follow-up > 12 months). Despite this clear superiority of the conventional four-drug polychemotherapy, there was some suggestion that IFN might be particularly active in cases with low tumor-burden (stage I, II), and light-chain or IgA paraprotein type.

Original languageEnglish
Pages (from-to)1111-1116
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number9
DOIs
Publication statusPublished - 1986

Fingerprint

Paraproteins
Melphalan
Prednisolone
Combination Drug Therapy
Multiple Myeloma
Cyclophosphamide
Tumor Burden
Immunoglobulin A
Interferons
Kidney
Light
Therapeutics
Pharmaceutical Preparations
interferon alfa-2c

ASJC Scopus subject areas

  • Oncology

Cite this

Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma : a prospective randomized trial. / Ludwig, H.; Cortelezzi, A.; Scheithauer, W.; van Camp, B. G K; Kuzmits, R.; Fillet, G.; Peetermans, M.; Polli, E.; Flener, R.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 9, 1986, p. 1111-1116.

Research output: Contribution to journalArticle

Ludwig, H. ; Cortelezzi, A. ; Scheithauer, W. ; van Camp, B. G K ; Kuzmits, R. ; Fillet, G. ; Peetermans, M. ; Polli, E. ; Flener, R. / Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma : a prospective randomized trial. In: European Journal of Cancer and Clinical Oncology. 1986 ; Vol. 22, No. 9. pp. 1111-1116.
@article{f875ae0353d94536bd0f24b59e2e6866,
title = "Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial",
abstract = "Forty-two previously untreated patients with multiple myeloma were entered in a prospective, randomised trial comparing recombinant interferon alfa-2C monotherapy with VMCP (vincristin, melphalan, cyclophosphamide and prednisolone). Both treatment arms were comparable for the stratification variables such as paraprotein type, stage of disease, and renal function. Rec. interferon effected 14{\%} responses and 29{\%} minor responses, while 57 and 32{\%} of VMCP-treated patients achieved a pathologically documented remission (P <0.001). The time on initial treatment was significantly shorter in the IFN group (3.2 months) than in the VMCP group (7.6 months). In four patients in the IFN arm, primary treatment had to be changed according to progressive or severe stationary disease. Since all four patients responded to second line therapy (VMCP) no significant difference has been observed between the two groups in survival (median follow-up > 12 months). Despite this clear superiority of the conventional four-drug polychemotherapy, there was some suggestion that IFN might be particularly active in cases with low tumor-burden (stage I, II), and light-chain or IgA paraprotein type.",
author = "H. Ludwig and A. Cortelezzi and W. Scheithauer and {van Camp}, {B. G K} and R. Kuzmits and G. Fillet and M. Peetermans and E. Polli and R. Flener",
year = "1986",
doi = "10.1016/0277-5379(86)90015-5",
language = "English",
volume = "22",
pages = "1111--1116",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma

T2 - a prospective randomized trial

AU - Ludwig, H.

AU - Cortelezzi, A.

AU - Scheithauer, W.

AU - van Camp, B. G K

AU - Kuzmits, R.

AU - Fillet, G.

AU - Peetermans, M.

AU - Polli, E.

AU - Flener, R.

PY - 1986

Y1 - 1986

N2 - Forty-two previously untreated patients with multiple myeloma were entered in a prospective, randomised trial comparing recombinant interferon alfa-2C monotherapy with VMCP (vincristin, melphalan, cyclophosphamide and prednisolone). Both treatment arms were comparable for the stratification variables such as paraprotein type, stage of disease, and renal function. Rec. interferon effected 14% responses and 29% minor responses, while 57 and 32% of VMCP-treated patients achieved a pathologically documented remission (P <0.001). The time on initial treatment was significantly shorter in the IFN group (3.2 months) than in the VMCP group (7.6 months). In four patients in the IFN arm, primary treatment had to be changed according to progressive or severe stationary disease. Since all four patients responded to second line therapy (VMCP) no significant difference has been observed between the two groups in survival (median follow-up > 12 months). Despite this clear superiority of the conventional four-drug polychemotherapy, there was some suggestion that IFN might be particularly active in cases with low tumor-burden (stage I, II), and light-chain or IgA paraprotein type.

AB - Forty-two previously untreated patients with multiple myeloma were entered in a prospective, randomised trial comparing recombinant interferon alfa-2C monotherapy with VMCP (vincristin, melphalan, cyclophosphamide and prednisolone). Both treatment arms were comparable for the stratification variables such as paraprotein type, stage of disease, and renal function. Rec. interferon effected 14% responses and 29% minor responses, while 57 and 32% of VMCP-treated patients achieved a pathologically documented remission (P <0.001). The time on initial treatment was significantly shorter in the IFN group (3.2 months) than in the VMCP group (7.6 months). In four patients in the IFN arm, primary treatment had to be changed according to progressive or severe stationary disease. Since all four patients responded to second line therapy (VMCP) no significant difference has been observed between the two groups in survival (median follow-up > 12 months). Despite this clear superiority of the conventional four-drug polychemotherapy, there was some suggestion that IFN might be particularly active in cases with low tumor-burden (stage I, II), and light-chain or IgA paraprotein type.

UR - http://www.scopus.com/inward/record.url?scp=0022540433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022540433&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90015-5

DO - 10.1016/0277-5379(86)90015-5

M3 - Article

C2 - 3536528

AN - SCOPUS:0022540433

VL - 22

SP - 1111

EP - 1116

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -